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Mutations in EZH2 Cause Weaver Syndrome
William T. Gibson,1,2,* Rebecca L. Hood,3,4 Shing Hei Zhan,5 Dennis E. Bulman,4 Anthony P. Fejes,5
Richard Moore,5 Andrew J. Mungall,5 Patrice Eydoux,1,6 Riyana Babul-Hirji,7 Jianghong An,5
Marco A. Marra,1,5 FORGE Canada Consortium,12 David Chitayat,7,8 Kym M. Boycott,9
David D. Weaver,10 and Steven J.M. Jones1,5,11
We used trio-based whole-exome sequencing to analyze two families affected byWeaver syndrome, including one of the original families
reported in 1974. Filtering of rare variants in the affected probands against the parental variants identified two different de novo muta-
tions in the enhancer of zeste homolog 2 (EZH2). Sanger sequencing of EZH2 in a third classically-affected proband identified a third de
novo mutation in this gene. These data show that mutations in EZH2 cause Weaver syndrome.Weaver syndrome [MIM 277590] is a rare congenital
anomaly syndrome first described in two families in
1974.1 It consists of generalized overgrowth, advanced
bone age, marked macrocephaly, hypertelorism, and char-
acteristic facial features. Intellectual disability is common.
Approximately 40 cases are known from the literature.
Typically, Weaver syndrome occurs as a sporadic condi-
tion, though cases of parent-to-child transmission have
been documented.2,3 Some patients thought to have
Weaver syndrome have mutations in NSD1, which is
mutated or deleted in most patients with classic Sotos
syndrome [MIM 117550].4–6 This molecular finding has fu-
elled debate among clinical geneticists regarding whether
the Sotos andWeaver syndromes represent variable expres-
sivity of a single locus with allelic heterogeneity or
whether they represent distinct disorders caused by muta-
tions in different genes. Clinical features shared by both
syndromes include developmental delay, overgrowth,
and prominent macrocephaly, and features distinguishing
Weaver syndrome from Sotos syndrome are retrognathia
with a prominent chin crease (sometimes described as
a stuck-on chin), increased prenatal growth, and a carpal
bone age that is greatly advanced compared to metacarpal
and phalangeal bone age.
Whole-exome sequencing (WES) facilitates the identifi-
cation of sequence changes in the protein-coding genome
in small families and has enabled identification of rare and
ultrarare Mendelian disorders that have hitherto been
refractory to linkage mapping.7,8 To search for disease-
causing alleles in Weaver syndrome, we collected saliva-
derived DNA by using kits (Oragene) from one of the
probands included in the original report describingWeaver
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parents. We obtained informed consent from the parents,
assent from the affected individuals, and ethical review
and approval according to the Finding of Rare Disease
Genes (FORGE) Canada Consortium. Probands 1 and 2
were personally examined by D.D.W., who also reviewed
photos and clinical details on proband 3 (examined in
childhood; records of examination and referral provided
by D.C.; proband was reexamined in adulthood by
W.T.G.); probands were confirmed in childhood to have
classical features of Weaver syndrome and not Sotos
syndrome (Figure 1 and Table 1), and parents were
confirmed to be unaffected. None of the three probands
had submicroscopic abnormalities detectable by microar-
ray analysis (Illumina Human Omni2.5-Quad chip,
analyzed with CNVPartition from GenomeStudio
V2010.3). None of the probands had expanded FMR1
alleles [MIM 309550] or abnormalities on clinical karyo-
typing. We also ruled out rare variants in NSD1 [MIM
606681] by using Sanger sequencing on saliva-derived
DNA in all three probands (data not shown, primers avail-
able on request).
We performed exome sequencing on samples from six
individuals (probands 1 and 2 and the parents of both),
and quantified the DNA concentration by using a Quant-iT
dsDNA HS assay kit and a Qubit fluorometer (Invitrogen).
We sheared approximately 500 ng DNA for 75 s at a
duty cycle of 20% and an intensity of 5 with a Covaris
E210 and size fractionated the DNA on an 8% polyacryl-
amide gel. We excised the 200–250 bp size fraction, eluted
it from the gel slice, and ligated it to Illumina paired-end
adapters following a standard protocol as previously
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Figure 1. Proband from Weaver et al.1 and Two Additional Probands Described in This Study
Proband 1 is shown at 18months (A), 6 years (B), 11 years (C), 17 years (D), 21 years (E), and 30 years (F, G, and H). Proband 2 is shown at
age 7 years (I) and 13 years (J, K, and L). Proband 3 is shown at birth (M), 12 months (N), 24 months (O), 42 months (P), 6 years (Q),
10 years (R), 11 years (S), 16 years (T), and 19 years (U and V). Proband 3 at 8 years in a stance that shows elbow and knee contractures
(W). Photos are published with the proxy consent of the parents and assent of the probands.
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Table 1. Phenotypic Manifestations of Weaver Syndrome in Patients with EZH2 Mutations
Phenotypic Manifestation
Proband 1 c.457_459del
(p.Tyr153del)
Proband 2 c.2080C>T
(p.His694Tyr)
Proband 3 c.394C>T
(p.Pro132Ser)
Gestational age at delivery (weeks) ~36.5 32 42
Birth weight (kg) 4.82 3.26 4.50
Birth length (cm) 55.0 50.8 55
Birth head circumference (cm) 36.5 ~34 Nk
Recent weight (kg) [age measured] 118 [30 years] 64.1 [10 years, 11 months] 103.3 [19 years, 9 months]
Recent height (cm) [age measured] 190.5 [30 years] 179 [10 years, 11 months] 177.7 [19 years, 9 months]
Excessive growth of prenatal onset þþþ þþþ þþþ
Accelerated osseous maturation þþþþ þþþþ þþþþ
Neurological Features
Hypertonia þþ – –
Hypotonia – þþ þþ
Hoarse, low-pitched cry þþ þþ þþ
Intellectual disability mild borderline-mild mild
Excessive appetite þþ þþ –
Ventriculomegaly þþ Nk –
Delayed myelination Nk Nk þ
Cerebellar hypoplasia (mild) – Nk þ
Seizures (age of onset) tonic-clonic [13 years] – brief absence [15 years]
Poor fine motor coordination þþ þ þþ
Poor balance and gravitational insecurity þþ þþ þþ
Fatty filum terminale – – þþ
Craniofacial
Macrocephaly þþþ þþþ þþþ
Large bifrontal diameter þþþ þþþ þþþ
Flat occiput þ – þ
Large ears þþþ þ þ
Ocular hypertelorism þþ þþ –
Downslanted palpebral fissures þ þ þ
Long philtrum þþ þþ þþ
Retrognathia þ þ þ
Cardiovascular
Patent ductus arteriosus – – þ
Hands
Prominent digit pads þþ þþ þþ
Single transverse palmar crease – – –
Camptodactyly þþ þ –
Broad thumbs þþ þþ –
Thin, deep-set nails þþ þþ þþ
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Table 1. Continued
Phenotypic Manifestation
Proband 1 c.457_459del
(p.Tyr153del)
Proband 2 c.2080C>T
(p.His694Tyr)
Proband 3 c.394C>T
(p.Pro132Ser)
Feet
Clinodactyly, toes þ þ –
Talipes equinovarus þþ – –
Short fourth metatarsals þ – –
Hind foot valgus – – þ
Limited elbow and knee extension in early life þ – þ
Limited elbow and knee extension after puberty þ – þ
Widened distal femurs and ulnas þþ Nk –
Skin
Excessive loose skin þþ þþ –
Inverted nipples þ – –
Thin hair þ – –
Increased pigmented nevi – þþ þþ
Connective Tissue
Umbilical hernia þþ þ þ
Inguinal hernia þþ – –
Scoliosis (degrees) 20 10 16
Endocrine
Hypothyroidism [age of onset] ~25 years – –
Growth hormone deficiency [age of onset] ~27 years – –
Key: þ ¼ minimally present, þþ ¼ obviously present, þþþ ¼ very prominent, þþþþ ¼ severe, – ¼ assessed and found to be absent, Nk ¼ not known.cycles with the PE primer set (Illumina) and purified. The
pre-exome capture library DNA was assessed with an Agi-
lent DNA 1000 Series II assay and subsequently hybridized
500 ng to the 50 Mb exon probe with the Human All Exon
Kit (G3370) following Agilent’s SureSelect Target Enrich-
ment protocol. The captured DNA was purified with a
QIAGEN MiniElute column, and amplified for 12 cycles
with the standard Illumina PE primer set. PCR products
were separated by size on an 8% PAGE gel before gel extrac-
tion at the desired size range (320–370 bp). The samples
were then assessed with an Agilent DNA 1000 series II
assay. The final library was diluted to a concentration of
10 nM, which was confirmed via a Quant-iT dsDNA HS
assay kit and a Qubit fluorometer as above, prior to cluster
generation and exome sequencing.
We performed paired-end tag (PE100) sequencing with
an Illumina HiSeq2000 machine. Sequencing reads that
failed chastity filtering were removed with Illumina’s GA
Pipeline (1.12.0 RTA 1.12.4.2), and the remaining reads
were mapped to the reference genome sequence (hg18)
with BWA 0.5.7;10 duplicate reads and reads with a
mapping score of 0 were removed. The aligned reads
were exported to pileup format and called with SAMtools
0.1.13.11 We filtered single nucleotide variants and re-
tained those with a minimum SNP quality of 20 at varFilterThe AmericparameterD 1000. Small insertions and deletions (indels)
were processed similarly with varFilter parameters D
1000, d 2 and l 30. We then imported all the variants
into a local PostgreSQL database used to store and process
human variation data.12 We annotated the filtered
variants as known or novel depending on whether they
had been previously reported in a public database such as
dbSNP13 or the 1000 Genomes Project14 or previously
observed in the in-house database of normal germline
genomes sequenced at the British Columbia Cancer
Agency, Genome Sciences Centre (BCGSC). Currently,
this database contains over 1.47 billion observed sequence
variants mapping to 63.9 million unique base substitu-
tions derived from over 1,360 individuals. Specifically,
we sought to identify variations that cause nonsynony-
mous changes in protein-coding regions and those that
fell within two bases of exon boundaries (such that
they might interfere with intron splicing; Table S1, avail-
able online).
In proband 1, we identified a heterozygous c.457_459del
(p.Tyr153del) variant in isoform A of EZH2 [MIM 601573]
(RefSeq NM_004456.4). This was not seen in either of his
parents, indicating that this was a de novo mutation. We
also identified a heterozygous de novo missense variant
c.2080C>T (p.His694Tyr) of the same gene in proband 2.an Journal of Human Genetics 90, 110–118, January 13, 2012 113
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Figure 2. Sanger Confirmation of Sequence Variants
(A) The c.457_459del mutation in Proband 1 (curly bracket) is
de novo.
(B) The c.2080C>T mutation in Proband 2 (arrow) is de novo.
(C) The c.394C>T mutation in Proband 3 (arrow) is de novo.These variants were seen at high coverage in both
probands (in 121 out of 239 reads and in 153 out of 304
reads, respectively) but were not seen in the parental reads.
In our hands, coverage at this level has a positive predictive
value of 100% for subsequent Sanger verification. We went
on to validate the presence of both of these mutations and
their de novo status by using Sanger sequencing (Figure 2,
primers available on request). After filtering out parental
variants, no other gene demonstrated private mutations114 The American Journal of Human Genetics 90, 110–118, January 1in both of the probands (Table S1), where ‘‘private’’ is
defined as not found in dbSNP, 1000 Genomes Project
data, or among normal genomes (including the parents
of the probands) sequenced in-house at the BCGSC. We
then analyzed EZH2 by Sanger sequencing in a third trio
(proband 3 and her parents) in whom we had not per-
formed exome sequencing. We identified a c.394C>T
(p.Pro132Ser) mutation in Proband 3 and confirmed that
it was de novo (i.e., absent in both parents).
The p.Tyr153 del mutation in Proband 1 lies six amino
acid residues from the N terminus of the Simple Modular
Architecture Research Tool (SMART)15-predicted SANT
(switching-defective protein 3 [Swi3]), adaptor 2 [Ada2],
nuclear receptor corepressor [N-CoR], transcription factor
[TF]IIIB0) domain (Figure 3, annotated with InterPro16).
The deletion of an entire amino acid (p.Tyr153del) in
EZH2 removes a bulky polar residue near the putative
SANT DNA-binding domain, which is suggestive of func-
tional consequences for the protein. Also, the deleted
codon is evolutionarily conserved according to phyloP.17
The placental mammalian genome-wide alignment-based
phyloP score averaged across the three codon sites (chro-
mosome 7:148,157,778–148,157,780) is 1.59 (taken from
the UCSC Genome Browser18 Conservation track for the
hg18 assembly). A positive phyloP score is interpreted as
a signature of evolutionary conservation, which is consis-
tent with functional importance.
The Sorting Intolerant From Tolerant (SIFT)19,20
scores for p.Pro132Ser and p.His694Tyr were 0.00 (with
values % 0.05 interpreted as damaging). With Poly-
Phen221 trained on the HumDiv data set, p.Pro132Ser
and p.His694Tyr were both predicted to be probably
damaging. Additionally, the nucleotide site (chromosome
7:148,157,843) where Pro132 occurs has a placental
mammalian phyloP score of 3.17, and the nucleotide site
(chromosome 7:148,137,365) where His694 occurs has
a score of 2.90. The positive phyloP scores suggest that
these nucleotide sites are evolutionarily conserved,
whereas a score near 0 would have suggested neutral
selection. Perhaps the most suggestive evidence for the
pathogenicity of p.His694Tyr comes from the specificFigure 3. Schematic of Human EZH2
Coding exons are indicated by rectangles
and noncoding exons by open rectangles.
The exons are numbered starting from
the exon containing the 50 untranslated
region (UTR). The putative SANT DNA-
binding domain is shown in orange, the
SET domain in blue, and the WD-binding
domain in green. The SMART or Pfam
domain identifier is presented in paren-
theses. Exons with no InterPro annotation
are indicated in gray.
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Figure 4. Ribbon Model of the EZH2 SET Domain
The wild-type histidine residue is shown in blue and the bulkier
tyrosine in white and red. The nearby binding site of the S-Adeno-
sylmethionine cofactor is also indicated.location of this histidine residue—it is located in the
Su(var)3,9, Enhancer of zeste, Trithorax (SET) domain,
within the knot substructure of the active site, and is
predicted to form part of the binding domain for the enzy-
matic cofactor S-adenosyl-L-methionine (AdoMet).22 We
made a 3D model of human EZH2 p.His694Tyr by using
SWISS-MODEL23 and ICM software24 (Molsoft) based on
the structure of the related protein euchromatic histone-
lysine N-methyltransferase 1 ([MIM 607001] selected
because of its lack of gaps and high-resolution crystal struc-
ture [1.6 A˚]; see Figure 4).25 The conformation of this
conserved histidine is highly similar across known crystal
structures for the SET domain. Because of its proximity to
the AdoMet-binding site, replacement of this histidine
with a bulkier tyrosine side chain could well interfere
with cofactor binding and methyltransferase activity of
the mutant molecule. Mutation of the histidine residue
that occupies a similar position in SUV39H1 abolished its
methyltransferase activity in an invitro assay,26 andamuta-
tion of this specific histidine residue to arginine (with func-
tional effects) has been reported in a 41-year-old male with
chronic myelomonocytic leukemia.27 Furthermore, muta-
tions in nearby residues at positions 690 and 693 were
also reported in other hematological malignancies.27
The EZH2 protein partners with SUZ12 and EED to form
the polycomb repressive complex (PRC2). This complex
catalyzes the trimethylation of lysine 27 of histone H3
(H3K27), and EZH2 itself forms the catalytic subunit for
this reaction. Thus, EZH2 forms a key component of
molecular machinery that shuts off transcription of loci
to which trimethylated H3K27 is bound. EZH2 is known
to be mutated somatically in lymphoid and myeloid
cancers.9,27 Mutation of arginine 690 to histidine or histi-
dine 694 to arginine appears to block EZH2’s ability to
facilitate trimethylation of H3K27,27 andmutation of tyro-
sine at position 641 also alters the affinity of EZH2 for
H3K27.28 Residues other than tyrosine at position 641
reduce the preference for unmethylated and monomethy-The Americlated lysine and favor trimethylation of lysine.28 It is worth
noting that some patients with Weaver syndrome have
been reported to develop tumors or malignancies,
including acute lymphoblastic leukemia.29 The lifetime
risk of malignancy in Weaver syndrome patients has
been estimated at 11%, though this is likely an overesti-
mate because of reporting bias. Nevertheless, constitutive
EZH2 mutations might confer a mild predisposition to
malignancy. Mutations that conferred a more profound
effect on histone methylation might also confer a stronger
selective advantage for cell growth. Such mutations might
not be viable in the fully heterozygous state and would be
observed in nature only as postzygotic somatic mutations.
In vitro studies will be required to determine whether the
p.His694Tyr mutation we have observed in this study
affects the affinity of EZH2 for AdoMet and whether any
of the three mutations affect H3K27 trimethylation.
It is clear from the resulting phenotypes that EZH2
mutations and structural variants also affect developmen-
tally important pathways. Several patients with deletions
and duplications encompassing EZH2 are reported in
the DECIPHER database (Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl
Resources),30 and one patient with a duplication (patient
250841) does manifest macrocephaly. The fact that there
is little other concordance between the DECIPHER pheno-
types (apart from intellectual disability) and those of our
patients is likely attributable to the multiple other genes
affected by these structural variants. It is also possible
that the EZH2 protein variants expressed in our patients
act throughmolecular mechanisms other than haploinsuf-
ficiency; subtle but important changes in specific subfunc-
tions of EZH2 are known to occur in association with
specific protein variants.28
Animal studies are yielding insights into the specific role
of mouse Ezh2 in organ systems other than the hemopoi-
etic system. Ezh2 regulates proximodistal axis elongation
and anteroposterior axis specification in the developing
mouse limb.31 Limb anomalies in humans with Weaver
syndrome are relatively mild, though deep-set nails, joint
contractures, and dysharmonic bone age might be conse-
quences of aberrant EZH2 signaling in human limb
patterning. Mice with targeted knockout of Ezh2 in beta
cells had reduced beta cell proliferation and beta cell
mass,32 and mice with targeted knockout of Ezh2 in satel-
lite cells had impaired regeneration of muscle.33 None of
our three probands had elevated fasting glucose, though
probands 2 and 3 continue tomanifest hypotonia (Table 1).
Several patients with Weaver syndrome are reported to
have mutations in NSD1, a gene first associated with over-
growth in the Sotos syndrome.4–6 NSD1 mutations in
Weaver syndrome appear to cluster toward the C terminus
of the molecule, 50 of the SET domain, though one frame-
shift mutation in exon 5 and one mutation within the SET
domain itself have been reported.5 Direct protein-protein
interactions between EZH2 and NSD1 are not yet known,
but the similarity of the human phenotypes caused byan Journal of Human Genetics 90, 110–118, January 13, 2012 115
rare mutations in these genes suggests interactive links
between gene networks containing these two SET-
domain-containing proteins.
Our data demonstrate de novo mutations in EZH2 in
three families, including one of the original families that
led to the definition of the disorder. These results illustrate
the power of next-generation sequencingmethods to iden-
tify rare disease-causing variants with a small number of
samples (six individuals in this case, only two of whom
are affected), provided that detailed clinical studies first
identify phenotypic concordance and additional families
are available as a replication set. BecauseWeaver syndrome
is a genetically heterogeneous condition, other genes asso-
ciated with the condition might yet be identified.
Finally, it is interesting to note the involvement of SET-
domain proteins in molecular networks that, when per-
turbed, cause intellectual disability syndromes and/or
cancer. Mutations in NSD1 cause Sotos syndrome and
Weaver syndrome,4–6 and mutations in MLL2 (which also
bears a SET domain) cause Kabuki syndrome.34 Histone-
modifying proteins such as NSD1, EZH2, andMLL2 appear
repeatedly as targets of somatic mutation in hematological
malignancies35 and are emerging as a cause of neurodeve-
lopmental disorders. Detailed studies of larger cohorts of
well-phenotyped probands will assist in determination of
the prevalence of mutations in EZH2 and other SET-
domain proteins in Weaver and other syndromes and of
their consequences on metabolism and cancer risk. At
this time, the evidence from animal models is insufficient
to recommend routine surveillance in Weaver syndrome
for diabetes or myopathy, beyond what would ordinarily
be performed in pediatric and adult practice. Data from
long-term follow-up of adult individuals with Weaver
syndrome will assist physicians in deciding the optimal
time to screen for potential metabolic and neoplastic
complications of this rare disorder. The possibility that
dietary supplementation with methionine (or with other
methyl donors such as betaine and choline) might
improve the activity of certain EZH2 variants is attractive
but awaits further investigation.Supplemental Data
Supplemental Data include one figure and one table and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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